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Abstract
Introduction: The South American country Chile now boasts a life expectancy of over 80 years. As a consequence,
Chile now faces the increasing social and economic burden of cancer and must implement political policy to
deliver equitable cancer care. Hindering the development of a national cancer policy is the lack of comprehensive
analysis of cancer infrastructure and economic impact.
Objectives: Evaluate existing cancer policy, the extent of national investigation and the socio-economic impact of
cancer to deliver guidelines for the framing of an equitable national cancer policy.
Methods: Burden, research and care-policy systems were assessed by triangulating objective system metrics –
epidemiological, economic, etc. – with political and policy analysis. Analysis of the literature and governmental
databases was performed. The oncology community was interviewed and surveyed.
Results: Chile utilizes 1% of its gross domestic product on cancer care and treatment. We estimate that the economic
impact as measured in Disability Adjusted Life Years to be US$ 3.5 billion. Persistent inequalities still occur in cancer
distribution and treatment. A high quality cancer research community is expanding, however, insufficient funding is
directed towards disproportionally prevalent stomach, lung and gallbladder cancers.
Conclusions: Chile has a rapidly ageing population wherein 40% smoke, 67% are overweight and 18% abuse alcohol,
and thus the corresponding burden of cancer will have a negative impact on an affordable health care system.
We conclude that the Chilean government must develop a national cancer strategy, which the authors outline herein
and believe is essential to permit equitable cancer care for the country.
Keywords: Chile, Cancer policy, Investigation, Research and development, Statistics, Gallbladder cancer, Stomach cancer,
Developing country
Introduction
Chile: a complex demographic transition
The burden of cancer worldwide is rapidly increasing,
principally due the growth and ageing of the world popula-
tion, coupled with an increasing adoption of cancer-causing
lifestyles (eg. tobacco) in economically developing countries
[1]. It is anticipated that the developing world will bear the
brunt of cancer incidence and mortality in the coming
years [1]. By 2030 in Latin America/Caribbean region, it
is estimated that 1.7 million cases of cancer will be
diagnosed, resulting in more than one million annual
deaths [2]. Chile, a country of over 17.5 million people
(59th most populous country on Earth) [3], of which less
than 3% are immigrants [4], leads South America with
the lowest percentage of it population below the poverty
line. Furthermore, Chile also boasts the lowest regional
international debt and is the second leading country after
Brazil in international exports [5,6]. These socioeconomic
results associate with the incorporation of a westernized
lifestyle and an increase in life expectancy, which have
translated into an increase in cancer burden. Life
* Correspondence: jjimenez@med.puc.cl
1Department of Public Health, Pontificia Universidad Católica de Chile,
Santiago, Chile
8Biomedical Research Consortium Chile, Santiago, Chile
Full list of author information is available at the end of the article
© 2015 Jimenez de la Jara et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Jimenez de la Jara et al. Biological Research 2015, 48:10
http://www.biolres.com/content/48/1/10
expectancy in Chile currently stands at 80 years (77 years
for men and 83 years for women), placing it above the
average of both upper middle-income countries (74 years)
and high income countries (79 years) as estimated by
the World Health Organization and the Organization for
Economic Co-operation and Development (OECD) [7,8].
Half a century ago only a small percentage of the
Chilean population was of pensionable age, but based on
demographic statistics from the 2002 Chilean Census,
this figure was estimated by the Ministry of Health to be
12.9% in 2010, rising to 22.3% in 2030 and over 28% in
2050 (Figure 1) [9]. However, recent preliminary data
from the Ministry of Social Development indicates that
15.6% of Chileans were >60 years old in 2011, suggesting
that Chile may be underestimating the population age
structure and thus the burden of aging-related public
health in the coming years [10].
Chile’s health care system is mainly public and covers
some 75% of the population. A further 14% are insured by
private schemes, and the remaining population covered by
other mixed insurance systems. The change to a more
occidental lifestyle can also be clearly observed in Chile’s
socioeconomic structure. In a society stratified from A to
E, where ABC are high level earners and make up 5% of
the country, E is the poverty line (15% population) and D
is the majority of Chileans (75%), a clear separation in
cancer incidence has been reported [6].
Chile has belatedly implemented restrictions on tobacco
availability to minors. According to the 2013 Health statis-
tics, an average of 21% of each population within OECD
countries use tobacco-related products. However, the re-
cently compiled “Tobacco Atlas” by the American Cancer
Society and the World Lung Foundation estimates that
37.5% of men and 33.3% of women in Chile smoke. This
equates to a US$1.1 billion drain on the health service and
accounts for 11% and 8% of male and female mortality, re-
spectively. Alarmingly, 51.7% of Chile’s youth are exposed
to second-hand smoke within the home, and 28% of boys
under 15 and an incredible 39.9% of girls under 15 are
currently smoking. This latter statistic for girls un-
fortunately places Chile among the world leaders in
this category.
The estimated annual incidence of cancer in Chile is
approximately 35,000 new cancer cases per year, with ad-
justed incidence rates of 226 and 180 per 100,000 male
and female inhabitants, respectively [2,11]. Cancer regis-
tries in Chile currently do not have national coverage, and
thus incidence rates are principally estimated from death
certificates. Approximately 22,000 annual cancer deaths
are recorded, which accounts for 24% of national mortality
(92,000) [9]. Mortality statistics in Chile have highlighted
a cancer distribution that is both unique and of concern
[11]. In 1990 the mortality rate from cancer was 107 per
100,000 Chileans. In 2007 this figure increased to 129.5
per 100,000 and then again to 137.5 per 100,000 in 2011,
with rates for males and females manifesting similar
upward trends. The relative burden of cancer mortality
has been increasing steadily over the last decades: 8.4% in
1960, 12.1% in 1970, 15.8% in 1980, 18.1% in 1990 and
24% in 2011 [12].
Although the per capita income has more than qua-
drupled from US$5,000 in 1990 to over US$20,000 in
2012 (USD in Purchasing Power Parity) [13] and poverty
indexes have diminished from 40% to 15% during the
same period, the cancer burden profile has not transi-
tioned to which one would expect in a pure high income
country [13]. Thus, Chile fits the profile of a developing
country that the UN General assembly and the World
Health Organization have singled out as being the carriers
of the global cancer burden in the years to come [1,14].
Herein, we aim to quantitate the economic impact of
cancer in Chile and evaluate existing cancer policy. The
distribution and extent of national investigation in on-
cology and the socio-economic role of cancer will be
assessed. An overall objective is to deliver information
on the state of cancer in Chile and offer guidelines for
the framing of an equitable national cancer policy.
Methods
Epidemiological data was obtained from the literature and
on-going investigation from the authors. All database refer-
ences are included in detail in the reference section.
Total population statistics on Chile were obtained from
the World Population review, the CIA World Factbook
[6] and the Chilean National Institute of Statistics (Insti-
tuto Nacional de Estadísticas de Chile, INE) [15] websites.
Population projection data between 1950 and 2050 were
based on statistics from the INE: Demographics and Vitals
[9]. Further data was retrieved from the Ministry of Social
Development website [16], Government of Chile: National
Socioeconomic Characterization Survey, Casen 2011
[10]. World health and life expectancy data was obtained
from the OECD Health Statistics database (OECD Health
Data 2013) [8].
Quantifiable data
Analysis of population and economic burden
Raw data for the chronic disease burden in Chile was
collected from the publicly available databases from the
Ministry of Health website [17]: Proyecciones y Estima-
ciones de Población. Total País 1950–2050 [8] and Informe
Final Estudio de carga de enfermedad y carga atribuible,
2007 [18]. National statistics on mortality and population
were obtained from the National Institute for Statistics
[15]. Economic burden was based on Ministry of Health
data on hospital discharges correlated to pricelist re-
imbursement from both the public and private (ISAPRE)
sectors. The calculation of cancer in economic terms was
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determined by multiplying the Disability Adjusted Life
Years (DALYs) due to cancer by the equivalent of the Per
Capita income of the country, estimated at US$20,000
[19]. The calculation of the number of cancer related
patents solicited from Chile was compiled using the key-
words “Chile” together with either “tumor”, “neoplasms”
or “cancer” at the National Institute of Intellectual prop-
erty (Instituto Nacional de Propiedad Industrial, INAPI)
[20] and World Intellectual Property Organization (WIPO)
[21] webpages. The results were screened individually to
validate their relevance and authenticity.
Clinical trials data
A registry of clinical trials was obtained from National
Institute of Public Health Chile [22], the U.S. National
Institutes of Health clinical trials register [23], the European
Union clinical trials register [24] and through personal
communication with complying hospitals and clinics.
Cancer research expenditures
Information on project and cancer research expenditure
was obtained from the public databases from the National
Commission for Science and Technology (CONICYT) [25]
at the Ministry of Education and the Chilean economic
development agency (CORFO) [26] within the Ministry of
Economics. Additional data was obtained through the kind
donation of specific funding information pertaining to
biomedical consortia, science parks and personal com-
munication with individual institutions and scientists.
Trends in Chilean scientific cancer-related publications and
investigation
Scientific cancer-related publications (written in English
and Spanish), were calculated form searches in NCBI
PubMed database of the keywords “Chile” and “cancer or
neoplasms” from 1970 until 2013. The relevance of the re-
sults returned from the Pubmed database was scrutinized
for integrity to the search criteria. The Chilean national
medical journal, the Revista Medica de Chile, is indexed
on the NCBI Pubmed database. The increase in cancer-
related presentations at national conferences (principally
the The Annual Meeting of the Chilean Society for Cellular
Biology 2009–2013) was assessed by personal participation
of the authors at the meeting and a quantification of
cancer related studies listed among the abstracts and oral
presentations.
Questionnaires
Questionnaires were generated using the web-based pro-
gram survey monkey and were sent to all members inves-
tigators and medics identified by the national databases of
the ministries of health, economics and education. The
questions were restricted to the highest degree obtained,
the speciality, the publication record, financial support
won and affiliated institution. Medical doctors were asked
to divulge participation in international clinical trials and
all investigators (MD, PhD, BSc) who had obtained na-
tional or international funding in the area of cancer were
surveyed on their specific area of research. When informa-
tion could not be obtained from questionnaires, academic
Figure 1 Chile’s ageing population. Comparison of age cohorts (%) from 1950 projected to 2050 (Data source: CHILE: Proyecciones y Estimaciones
de Población. Total País 1950–2050 [9]).
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information and area of research for individual investiga-
tors was obtained from the public databases from
CONICYT and CORFO. This information was quantified
and represented graphically within this publication.
Results
Quantifying the economic burden of cancer in Chile
In developed countries the economic impact of a disease
is a major public policy issue. In Chile, where 23.8% of
national mortality is due to cancer (Figure 2), we have
calculated that Chile currently spends US2.100 million
(1% GDP) on cancer care and treatment. Calculating the
chronic disease burden in Chile we see that cancer
accounts for notable proportions of Years Lost due to
Disability (YLD) and Years of Life Lost due to premature
death (YLL). Disability-Adjusted Life Years (DALYs) cor-
responds to the sum of YLD + YLL (Figure 2). Whilst no
formal economic studies of the burden of cancer have
been conducted in Chile, the authors of this paper have
estimated that the national income lost to cancer per
year DALYs is US$ 3.5 billion. This value was achieved
by multiplying the calculated VLL (175,711) by an esti-
mated per capita income of US$20,000. This suggests
that cancer has a major economic impact in Chile. How-
ever, along with cancer, an aging population also brings
an increase in neuropsychiatric problems that will only
place further burden on the Chilean economy. The
absence of integrated health economic studies is notable
in Chile and in public policy terms this is a major deficit
that needs to be urgently rectified.
Stomach and gallbladder cancer: the Chilean
phenomenon
Based on world statistics, the Chilean population presents
notoriously higher than average mortality and incidence
rates for both stomach and gallbladder cancers [27,28].
Stomach cancer has historically been one of the principal
causes of cancer related death worldwide. However, while
rates have declined in westernized populations of North
America, Northern and Western Europe, regions such as
South America still post high mortality rates [29].
While stomach cancer is currently the most common
malignancy in Chile, in the United Kingdom (UK), stom-
ach cancer no longer figures as one of the ten most
common cancers, with the incidence rate having fallen
by over 60% since the mid-70s [30]. In 2009, Chile regis-
tered 3,350 deaths from stomach cancer giving a rate of
19.8 per 100,000 inhabitants [12].
As has been reported globally there is also a strong
correlation between stomach cancer and the indigenous
population [31]. This is also true in Chile, where be-
tween 1998 and 2002, a crude incidence rate of 29.2 per
100,000 inhabitants was reported in the city of Valdivia
in the mid-southern region of the country [27]. Most
stomach cancer patients are male, with urban residence
and a low level of schooling [27,32]. Along with social
determinants and advanced clinical stage at consultation,
infection with the bacteria Helicobacter pylori is also
recognized as a principal risk factor for stomach cancer in
the Chilean population [27,32]. In addition, Helicobacter
infection has been associated to lower socioeconomic
structure. This observation is in line with statistics
implicating the involvement of infection in 22.9% of
cancers in lower income countries, as opposed to 16%
globally [14,33].
Another factor in the Chilean stomach cancer story is
salt. In Chile, it is estimated that the average salt (NaCl)
consumption is around 10.4 g per day in adults [34,35].
This value is significantly higher than in British adults
who consume on average 8.1 g per day [36]. The inter-
action between salt, Helicobacter and genetic predis-
position in the Chilean population are likely to underlie
this high incidence. However, genetic factors aside, these
above mentioned risk factors suggest that prevention,
through health education and eradication of Helicobacter
pylori, together with better screening procedures for pre-
cancerous lesions may well deliver a notable improvement
in incidence and prognosis to the Chilean population.
While stomach pattern follows a worldwide trend in
reducing as socioeconomic status increases, a statistic
that is uniquely Chilean is the incidence of gallbladder
cancer [37]. In the UK, gallbladder is considered a rare
cancer, with 700 new cases and 438 deaths recorded in
2008 [38]. Chile recorded 1819 deaths from gallbladder
and bile duct related cancer in the same year. Further
emphasizing the gallbladder problem, in Chile the esti-
mated incidence and mortality rates for this cancer are
13.4 and 11.5 per 100,000 female habitants, while in
Latin-American these rate are 3.7 and 3.0, and in the
USA 1.6 and 0.6 respectively [39]. The highest risk group
for gallbladder cancer is among Amerindians, Mapuche
and Hispanic women with less than four years of school-
ing [28]. On the other hand, the lowest standardized inci-
dence rates were among Hispanic men and women with
more than eight years of schooling. Thus, ethnic origin,
low schooling, the female sex and urban residence were
deemed independent risk factors. In the Mapuche popula-
tion, the incidence of gallbladder cancer has reached 269.2
per 100,000 women in specific age groups [28]. Interest-
ingly, cholelithiasis is always a precursor to gallbladder
cancer, suggesting that screening programs and chole-
cistectomy could significantly decrease gallbladder can-
cer death. A pilot study of gallbladder cancer lead by
the US-National Institute of Health (NIH) (Government
trial identifier NCT01520259) in conjunction with Chilean
Universities intends to recruit 120 cases to assess the
feasibility of a full-scale population based multidisciplinary
gallbladder cancer study [40]. Another recognized risk
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factor is the chronic carriage of Salmonella typhi, which
would be the long-term effect of the hyperendemic of
Typhoid Fever that occurred in Chile during the 1970s
and 80s [41]. As Chile moves towards a more westernized
lifestyle, the risk factors and incidence are likely to fall,
however, the sheer numbers of gallbladder cancer cases in
Chile suggests a genetic or environmental factor that is
not being fully addressed by the nation’s scientific and
medical community [42].
Another malignancy that demonstrates peculiar statis-
tics in Chile is lung cancer. The majority of Chile pre-
sents slower than developed country incidence rates.
However, the occurrence of high arsenic exposure in
drinking water (>200 ug/L as opposed to now recom-
mended <10 ug/L) from 1930 to 1977 in the Antofagasta
Region in the north of the country and in particular levels
of 860 ug/L in the City of Antofagasta between 1958 to
1970 has resulted in high lung cancer incidence and
mortality [43]. Despite water filters and regulations
being introduced in the 1970s, a significantly high odds
ratio to develop lung and bladder cancer in this region
still exists up until today [44]. However, not all cancers
increased in mortality. A recent publication has specu-
lated a rapid reduction in breast cancer mortality in
the years during and directly following exposure to
arsenic-contaminated drinking water in Antofagasta
[45].
Obesity and cancer in the Chilean population
In the National Health Survey of 2009, it was reported
that over 67% of the surveyed population was overweight
with 25% obese. Over 88% of the population was
estimated to lead a sedentary lifestyle and an alarming
statistic was the appearance of a significant number (3.3%)
of morbidly obese females within the population [46,47].
In neighboring areas within Chile’s capital Santiago, girls
at private school underwent menarche six months later
that girls at a state run school. Obesity in this case appears
to be the smoking gun, with age of menarche correlating
almost perfectly with body mass index [48]. Unsurprisingly,
increased obesity numbers also correlated well with an
increase in type-2 diabetes from 6.3% in 2003 to 9.4% in
2010 [48]. Interestingly and again demonstrating inequality,
diabetes was three times more prevalent in members of
the society with lower schooling [48].
Chile is now part of the Latin American Consortium of
Studies in Obesity (LASO) [49] and it has also joined with
the United Nations sponsored schemes on obesity control.
The government statistics demonstrate that 24.5% of the
men and 33.6% of women are obese, placing Chile together
with Venezuela and Argentina in leading South America in
this category. A recent publication suggests that 20% of
Chilean cancers are directly related to obesity, with most
affected being endometrial (47%) in women, and esopha-
geal (35%) and pancreatic (31%) in men [39]. The authors
Figure 2 Chronic disease burden in Chile. DALY: Disability Adjusted Life Years; YLD: Years Lost due to Disability; YLL: Years Lost due to Death;
DALY corresponds to the sum of YLD + YLL (Raw data source: Chilean Ministry of Health) [18].
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of this publication conclude, again demonstrating Chile’s
rapid incorporation of a westernized lifestyle, that the inci-
dence of obesity-related cancers resembled the distribution
of the USA and the UK more than developing countries
[39]. Obesity-related health problems maybe confounded
in coming years by the observation of increased gallstone
incidence in obese and overweight children [50]. This,
coupled to the observation that all gallbladder cancer
patients first present gallstones, may further increase
Chile´s notorious burden of gallbladder cancer.
Analysis to allow the development of a cancer healthcare
system in an emerging economy
Despite persistent inequalities in cancer distribution, the
Chilean population now has greater access to a public and
private health system than a decade ago. Provision of
services is mainly delivered by public sector services with
an overlay of private providers under contract with public
insurance system. The Ministry of Health is responsible
for setting public policy in health including cancer preven-
tion and mandatory strategies for infections, and chronic
disease including cancer and mental conditions [51]. The
2005 Health Reform established a set of guarantees for
access, care and quality for a significant number of health
conditions including some cancers [52,53]. This reform
has impacted positively in coverage and equity in health-
care across the Chilean population, including cancer. On
the delivery side, the public system runs a network of
Primary Health care, with around 1500 points of service
managed by municipalities in a decentralized mode.
Regional Health care services administer 60 hospitals
tasked with complex case management (tertiary), 100 less
complex hospitals (equivalent to secondary or district level
care) and a small number of highly specialized institutes
(e.g. Neurosurgery, Cardio-respiratory, and Cancer) [54].
Currently, Chile only offers first line therapy within the
public system, and there is also a need to re-consider the
overall quality and delivery of radiotherapy, surgery and
pathology to assess what Chile’s essential cancer guidelines
should or should not include.
Chile currently possesses 60 oncologists (data kindly
supplied by the Chilean Society of Medical Oncology), a
number clearly inadequate to meet the pending cancer
burden. To achieve the same coverage of oncologists per
capita currently present in the USA, Chile would have to
increase their number of oncologists to over 500. This
statistic mirrors the overall observation that Chile pos-
sesses only 1.6 medical doctors per 1000 inhabitants as
opposed to the OECD average of 3.2 medics per 1000
inhabitants.
Clinical trials
In the clinical trial registry at the Chilean National Institute
of Health (ISP Chile), 65 cancer clinical trials were active or
in progress in 2014 [55]. Most of them (76.9%) are phase
II/III or III and only 4.6% are in early phases (IB or I/II).
The majority support comes from outside the country with
Roche accounting for 10% of trials, Pfizer 7.6%, Bristol-
Myers Squibb 7.6%, Merck Sharp and Dohme 6.6% and
Amgen 6.6%. Through GOCCHI (Grupo Oncológico
Cooperativo Chileno de Investigación) [56], a Breast Inter-
national Group member, Chile is involved in multicenter
trials such as the US-LA-CRN (United States-Latin-
American- Cancer research Network) trial looking into the
molecular profiling of stage I and II breast cancers in
Latin-America and the worldwide ATLAS trial (Adjuvant
Tamoxifen: Longer Against Shorter) [57,58].
Cancer registries, tumor banks and legislation
Chile is in the initial stages of establishing and implement-
ing a regulatory legal framework in biomedical scientific
research. Chile is in transition from technical standards,
focused exclusively on clinical trials (Technical Standard
No. 57 of 2001), to specific legislation encompassing all
biomedical research (Law No. 20120 of 2006 [59] and its
Regulatory Decree No. 114 of 2010 [60], as amended in
2013 [61]). However, there are imperfections in this legal
framework that require urgent clarification to permit bio-
banking, biomedical research and the participation of
Chilean subjects in clinical trials.
Chile currently possesses a national registry of pediatric
cancers [62] and three established regional cancer registries.
The established registries, two of which are IACR (Inter-
national Association of Cancer Registries) registered [63],
provide incidence data from populations in the North
(Registro de cancer de Antofagasta) [64] and South (Registro
de cancer de Valdivia and Bio-Bio) of the country [65,66].
Together with the established registries, there are three
registries in development (Región de Arica-Parinacota,
Región del Maule, Provincia de Concepción), which when
fully operational should give vigilance of 18.5% of the coun-
try. Despite persistent underfunding, often only having one
part-time worker, these six databases have provided key in-
formation about the most frequent cancers in the country.
However, approximately 40% of the Chilean population is
centralized in the capital Santiago, and there are no imme-
diate plans to monitor cancer incidence in this region.
Through involvement in clinical trials such as the above
mentioned US-LA-CRN, Chile created its first centralized
biobank for breast tumor samples. The concept and re-
quirement for tumor banking in Chile is gathering mo-
mentum, however, while public universities and several
private universities and clinics have started to implement
banking systems, there is no collective consensus on
methodology and little interaction between the players.
This is principally due to a lack government priority,
regulatory confusion on the legal aspects of sample taking
and a scarcity of funding.
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Review and analysis of public policy approaches
to cancer in Chile
There is no National Cancer Policy in Chile. Nevertheless,
the Ministry of Health has established four programs re-
lating to cancer in the last 25 years. The four programs
are cervical cancer, established in 1987, anti cancer medi-
cines for children and adults in 1988, breast cancer in
1995 and palliative care in 1995. The Health Reform of
2005 also established Explicit Guarantees for Free Access
(GES) [67] in 15 conditions related to cancer [52,53].
Secondary prevention is included for four of these malig-
nancies: cervical cancer –Pap smear every three years from
ages 25 to 64, breast cancer–one mammography at age 50
years, stomach-endoscopy for symptomatic patients over
age 40, and cholecystectomy to prevent gallbladder cancer
in people aged 35 to 49. Furthermore, the public health
system offers diagnoses and treatment for testicular, pros-
tatic, lymphomas, palliative care and all cancer in children
under 15 years of age. In 2014 Chile passed an amendment
to the Labor Code, (new Article 66a) that states that female
workers over 40 years and male workers over 50 are enti-
tled to half a working day to undergo preventive medicine
exams (mammography, prostate exams, and Papanicolau
were specifically mentioned) [68,69]. Despite these programs,
screening coverage is still below the gold standard.
Chile’s neighbors Argentina and Peru [70], as in higher
income countries [71], offer several lines of chemotherapy
to cancer patients, while Chile is only now coming close
to full national coverage for first line therapies and imple-
menting the possibility of second line therapy. Several
prominent cancers in the country, such as lung cancer and
stomach cancer still do not have chemotherapy treatment
covered in the nation health plan. The Chilean Minister of
Health is currently preparing a legal initiative to cover
high costs drugs for low frequency diseases [72]. These
pathologies correspond to autoimmune disease and meta-
bolic disorders among others, however, this initiative may
well path the way for future high cost cancer therapies.
Analysis of cancer research in Chile
With excellence in care and improved outcomes so
dependent on having a learning cancer care system,
the state of R&D is a critical determinant of current and
future quality in any national cancer control system.
Scientific research in Chile has been historically sup-
ported by CONICYT, which is under the jurisdiction of the
Ministry of Education. In the time period of 2002–2012
Chilean state funds invested approximately US$55 million
in cancer research (Figure 3A). The majority of these funds
(US$33.2 million) came from the basic science grants
awarded by FONDECYT, with the more applied Ministry
of Education FONDEF grants contributing US$9.3 million.
FONDECYT grants have been rising steadily with the
number of new researchers taking up academic posi-
tions (Figure 3B). In 2002 seven Regular-FONDECYT grants
(USA RO1 equivalent) were awarded with an average of
US$ 42,000 per year for 3 years. In 2012 seventeen
Regular-FONDECYT grants with an average of US$ 100,000
per year were awarded. In the last decade FONDECYT has
also initiated an early investigator grant (FONDECYT
Inicio) that in 2012 awarded 5 cancer research projects
with an average of US$ 41,000 per year over 3 years.
Encouragingly, since 2011 the funds coming from the
Ministry of Economy (economic development board,
CORFO) have started to rise substantially. This is princi-
pally due to the increased emphasis that CORFO has
recently placed on innovation through science. Although
not all the figures are currently available to incorporate into
the graphs, this CORFO investment has continued to rise
in 2013 and 2014. In summary, the overall statistics demon-
strate a steady increase in cancer funding which is generally
in line with the number of new laboratory heads choosing
to dedicate their careers to cancer research. However, the
figures are still low when compared to other nations. Chile
spent US$12 million in cancer research in 2012, while
the National Cancer Institute (NCI-USA) budget was
US$ 4.9 billion for the same period.
Chile currently possesses 179 cancer investigators
(Figure 4A). A closer examination of human resources
demonstrates 126 investigators have been directly awarded
grant funding. Breaking down the investigators with fund-
ing into highest degree obtained, we see that that 12 are
MD/PhD (9.5%), 92 are PhD (73%), 14 are MD (11%), 3
MSc (2.4%) and 5 BSc (4%) (Figure 4B). Of the 65 medical
physicians questioned, 29 did not receive public funding
but participated work in international pharmaceutical
company projects (principally phase III trials) or intra-
departmental clinical protocols.
The distribution of cancer investigators is centered on
two universities; the University of Chile (Universidad de
Chile) and the Catholic University of Chile (Pontificia
Universidad Católica de Chile), both located in the capital
Santiago (Figure 5). These two universities between them
house 52% of national investigators and receive 67% of
national oncology funding (Figure 5A and B, respectively).
Both universities possess their own hospitals and a net-
work affiliated medical institutions offering cancer treat-
ment and care. In the last world university ranking survey
(http://www.topuniversities.com/), the Catholic University
of Chile was ranked 1st in Latin America and 166 world-
wide, while University of Chile was positioned 6th in Latin
America and 223 worldwide. Chile’s largest regional univer-
sity, the southern University of Conception (Universidad de
Concepción) houses 9% of the country’s cancer investigators
and receives 13% of national oncology funding. Despite the
classical dominance of these three universities in all areas
of scientific discipline in Chile, in recent years other
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principally private universities have started to establish can-
cer centers and attract highly qualified investigators. Not-
ably, the Universidad Nacional Andrés Bello, Universidad
del Desarrollo, Universidad Mayor, Universidad de Los
Andes, Clínica Las Condes and Fundación Ciencia & Vida
(Science & Life Foundation) have investigated heavily in the
field of oncology and may well compete with the leading
national universities in the not so distant future.
Breaking down the specific areas of oncology research
we see a similar pattern to that observed in many other
countries, where 27% of the funding is not designated to a
particular cancer type but utilizes cancer cell models
(represented as General in Figure 6A and B). Breast, colo-
rectal and prostate cancer between them account for 29%
of the researchers and funding. Of cancers with predomin-
ant incidence in Chile, only stomach cancer receives
sizable funds (10%), while lung cancer receives only 2%
and gallbladder cancer 4%. In other words, the cancers re-
sponsible for the majority of lives lost to cancer receive
only 16% of national funding. This finance figure roughly
reflects the number of researchers dedicated to these
cancers and thus the problem maybe manpower and not
funding priorities. A possible explanation for the shortage
of gallbladder cancer research is the training that the
Figure 3 State-subsidized investment in cancer research in Chile. A) Total Investment in cancer research 2002–2012 (US$ Millions). B) Investment
in cancer research (US$ Millions) by year between 2002 and 2012 according to public funding source.
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researchers received as post-doctoral fellows outside of
Chile. The cancer-types studied upon returning (or arriv-
ing) to Chile tend to be the malignancies studied in North
America or Europe, thus a high emphasis on breast and
prostate cancer and a low percentage of stomach and gall-
bladder cancers. The authors suggest an intervention from
the Ministry of Health and/or funding agencies to put an
emphasis on gallbladder, stomach and lung cancer. Epi-
demiological, access to medical care and preventative
research needs to be conducted hand in hand with the
cellular biology, genetic and epigenetic aspects of this
cancer, especially in relation to environmental factors.
An unexplained phenomenon in Chilean cancer research
is the lack of attention to lung cancer. Lung cancer is one
of the most funded cancers by the NCI-USA and one of
the biggest killers in Chilean society, yet accounts for only
4% of national researchers and 3% of funding. This statistic
may now change as the pharmaceutical company Pfizer
has recently been adjudicated funds by CORFO to investi-
gate bioinformatic components of South American lung
cancer patients [73].
Analysis of scientific productivity in Chilean cancer
research
Productivity can be measured in the publications, patents
and the formation of human resources. Analysis of the
current cancer publication record in Chile shows an up-
ward trend since the late 1980s with switch from Spanish
language to English language ISI-indexed journals since the
year 2000 (Figure 7). Encouraging, the increase in cancer
funding (Figure 3B) mirrors well the increase in cancer-
related publications, demonstrating that increased financial
investment is delivering higher scientific productivity.
Increased scientific funding has also permitted an increase
in doctoral students trained at Chilean Universities since
early 2000. Chile now boasts a steady flow of doctoral
Figure 4 Quantification of cancer researchers in Chile. A) Total number of investigators, separated into highest academic obtained, that have
performed cancer research in Chile. B) Total number of investigators, separated into highest academic obtained, who have received national
funds for the purposes of cancer research in Chile.
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students, albeit low in comparison to high-income coun-
tries. For example, the Catholic University of Chile has
graduated more doctoral students in the last decade that in
the 127 year history of the university (personal communica-
tion with university authorities). Other public and private
universities are following suit, while the government has
implemented schemes to finance doctoral theses in centers
of excellence outside the country [74]. As a result, at Chile’s
highest attended science meeting, The Annual Meeting of
the Chilean Society for Cellular Biology (approximately 700
participants), cancer-related presentations have risen from
1% to 16% during the last decade.
While many graduated students chose to stay in Chile, a
high percentage has undertaken at least one doctoral fellow-
ship in North America or Europe before returning to
academic positions in Chile. However, this encouraging
momentum may now start to slow, as long-term investment
in science is not creating new academic positions for return-
ing PhDs. Thus, as seen in other emerging economies, there
is a brain drain where students are trained at the cost of
Chilean taxpayer to benefit principally the research and
economy in North America [75]. Confounding this problem
is the hesitancy of the Chilean private sector to incorporate
PhDs and thus academia is often the only viable career path
for doctoral graduates. The culture in Chile for the private
sector (mainly pharmaceutical sector) to take an active role
in research did not exist a decade ago. The previous fragility
of the Chilean marketplace made the usual minimum 10-year
return on investigation, a horizon too distant to be considered
economically tangible. However, by requesting private-sector
partial funding and placing emphasis on research that may
result in patenting, CONICYT and CORFO have made
available additional public funds, some of which have gone
into cancer initiates. Halfway through the last decade the
Figure 5 Location of cancer research in Chile. A) Institutional affiliation of cancer-related investigators in Chile. B) Direct national funding received
by cancer-related investigators according to institutional affiliation (expressed as percentage of total funding obtained between 2002–2012).
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leading Chilean pharmaceutical company, Corporación
Farmacéutica Recalcine (purchased in 2014 by Abbott
Laboratories), started to co-sponsor cancer-related in-
vestigation at the leading universities. Although still few
in number, other companies have since followed their lead
in the research field. Andes Biotechnology, a Chilean
company formed from as a spin-off of Chile’s first Science
and Technology Park (Fundacion Ciencia & Vida) and the
private Andrés Bello University, is now able to boast the
first significant commercialization stemming from Chilean
based cancer research [76]. In the future, tax breaks and in-
centives could stimulate the private sector as a whole to
Figure 6 Areas of oncology research in Chile. A) Research categories of cancer-related projects for investigators who have received national
funding or participated in national or international clinical trials and protocols. B) Research categories of cancer-related investigation based on
financial allocation from national funds between 2002 and 2012.
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invest in research both for innovation of new products and
in the improvement of the processes within their own
manufacturing pipeline. A new law providing tax conces-
sions to private sector companies investing in R&D was
introduced in September 2012 [77].
A further parameter to measure investigation in cancer
research is the generation of intellectual property. Until
mid-2014 there have been 54 individual patent fillings
related to cancer from Chile, with over half of these
patent applications corresponding to new products. Since
the culture of patent applications has arrived late to the
Chile, this figure reflects well upon the translational-
orientation of national cancer investigators.
Conclusions
Cancer in transition: next steps for an emerging economy
in addressing cancer control
Chile, a country split into two unequal worlds of public
and private medicine, must work to guarantee fairness in
its cancer outcomes, as well as promote a national cancer
research system. Chile has a rapidly aging population
wherein 40% smoke, 67% are overweight, 18% abuse alco-
hol, 88% observe a sedentary lifestyle, and thus the corre-
sponding future burden of cancer will have a serious
negative impact on the Chilean society and the ability to
deliver an affordable health care system [11]. Accumulating
epidemiological evidence confirms that the socioeconomic
divide in Chile is a major factor in cancer incidence and
mortality and that this inequality is most notably mani-
fested in stomach and gallbladder cancers. Prime suspects
for the culpability of this socioeconomic divide are access
to the health system, lack of early detection, sanitary condi-
tions, working conditions and habits such as alcohol,
tobacco and diet. This striking social division for stomach
and gallbladder cancers highlights the need for education
and investigation to reduce the growing inequality. We
suggest that a future strategy for Chilean universities may
well be to initiate academic positions for investigators spe-
cializing in stomach, gallbladder and lung cancer. Further-
more, we suggest the initiation of scientific task force to
understand at the epidemiological, genetic and cellular
biology level the disproportionate incidence of gallbladder
in Chile. The task of the Ministry of Health must be to
define how and within a hypothecated budget, Chile can
address this major public health issue in terms of sustain-
able infrastructure, prevention strategies, and cost effective
care pathways. To address this issue, the authors have out-
lined in Table 1 (Key cancer public policy framing for the
Chile economy) their recommendations for Chile to tackle
the cancer burden. Although geared specifically to Chile,
this table may well offer a guideline for many other emer-
ging economies faced with a complex burden of cancer. By
far the greatest return on investment will be public
education and prevention, followed by screening and
early detection. The future action of Chile in the face of
the general international failure of population wide
mammograms [78] and prostate specific antigen testing
is a challenge [79,80].
Confounding this dilemma is the change in cancer
treatment from standard care to personalized medicine.
There will be a burden on the Ministry of Health to
adopt these new and expensive therapies. The last few
years have seen Chile implement the breast cancer drug
Trastazumab (Herceptin™) under the government fi-
nanced health plan. It could be reasonably argued that
the implantation of this treatment came about due to
public demand, in particular from breast cancer suf-
ferers and their families. With Chile’s continued growth
and future prosperity it will be morally and politically
unacceptable not to provide a national cost-effective cancer
Figure 7 Chilean cancer publication record (1970–2013). Trends in Chilean scientific cancer-related publications (written in English and
Spanish), as indexed in PubMed database.
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care system. Thus, infrastructure affordability, not just in
cancer treatment medicines, but also in the ever-updating
cancer technologies such as imaging, will need to be
addressed. On the other side of the coin is the danger of
taking on too many low-gain, high-price technologies.
There is an important need to make public policy in this
area evidenced based, affordable and fair to prevent un-
constrained exploitation by private interests. Equity
must be a central part of developing cancer public policy
and planning.
Chile now has the infrastructure, the economy and
the human capacity within the scientific community to
perform world-class cancer research. PhDs or MD now
conduct national cancer research and thus conditions
are clearly strong for additional investment in investiga-
tion. Overall positive trends in cancer outputs is a
strong metric that investing more in cancer research in
terms of public policy will generate returns on invest-
ment through knowledge and innovation. Moreover,
the mostly ISI-indexed English language publications
now heavy outweigh publications in Spanish language
journals (another metric of international quality). How-
ever, despite these positive trends the current investment
(public and private) is clearly insufficient to address the
magnitude of the problem, as only a small percentage of
the already scarce resources are invested in cancer re-
search. Currently, the problem in Chile is not principally
the number of grants available, as the basic research grant
(FONDECYT Regular) is now awarded to one in two ap-
plicants. The problem is the size and delegation of the
grants. Chilean researchers also face the additional prob-
lem of not having any local production of scientific agents
and suffer substantial taxation on any imported product
destined for scientific research.
While cancer policy should be initiated and delivered by
federal bodies, it is the grass roots of the medical cancer
and academic organizations that should drive public policy.
As many emerging economies pass through the period of
transition that Chile currently faces, it is important for
them not to try and reinvent the wheel, but instead look
outside for advice and guidance. There currently exist
several international collaborations driven by the Chilean
cancer community, notably with the NCI/NIH, IARC, MD
Anderson, the University of California and the King’s
Health Partners, London. These and other strategic collabo-
rations can play an important role in bringing Chile quickly
up to speed, through the implementation of off the shelf
solutions to promote cancer care and research infrastructure.
To achieve necessary changes, the impetus must come
initially from the Ministry of Health, with a public declar-
ation of intent to create a National Cancer Plan. Currently,
there is an evident asymmetry between the magnitude of
the cancer problem and important variables such as policy,
public awareness and equity. Although private-public dis-
cussion initiatives such as the National Cancer Forum have
been recently created [81], more effort in human resources,
planning, policy aspects and institutional development is
urgently required; and this will need to be cross depart-
mental, an additional challenge. It is important to highlight
the magnitude of cancer to Chilean society through all pos-
sible means, preceded by a national social interest study.
The analysis presented in this work clearly shows that
Chile is ready and needing of a National Cancer Policy.
Such a plan also needs a robust national cancer intelligence
Table 1 Key cancer public policy framing for the Chilean
economy
• Publicly recognize the imminent burden of cancer and implement
a strong and visible National Cancer Policy. Stimulate pro-equity
interventions in poor areas of the country.
• Introduce a national cancer law. Place cancer policy on the political
and public agenda and permit top-down implementations of cancer
policy in the country.
• Create integrated cancer hospitals. To start, these establishments
should be in the North (possibly Antofagasta), South (possibly
Concepcion or Valdivia) and in the capital city of Santiago. The
National Cancer Institute (Instituto Nacional de Cáncer) in Santiago
would be the prime candidate to transform into an integrated cancer
hospital.
• Conduct regular systemic nationwide studies on the status of
oncology at all levels. Perform regular evaluations of the impact
of health and cancer reforms. Promote studies of the economics
burden of cancer to inform a National Cancer Policy.
• Initiate nationwide prevention programs incorporating all sectors of
society. This should include stronger than the current emphasis on
tobacco use, salt consumption, increase consumption of fruit and
vegetables and decrease obesity, especially at schooling age.
Promote research into prevention strategies and introduce public
demystification and education in cancer, starting at the schooling age.
• Promote the investigation in cancers of high national relevance
(e.g. stomach, gallbladder and arsenic-related lung cancer in Chile).
We suggest the setting up of specific task forces promoting
multi-institutional team science. Lifting any import tax on reagents
and literature destined for education and scientific research.
• Partner with other South American countries to pool resources
on regional problems. Reach out to North American and European
countries for specialist help and off the shelf solutions to cancer-related
problems.
• Specifically focus on clinical trial promotion to stimulate
pharmaceutical company interest in Chile and clinical oncologist
participation in research.
• Promote incentives and tax breaks to further stimulate the private
sector investment, coupled with stimulation of capital risk and angel
investments in the biomedical field. Clarify national finance laws to
allow institutions to receive legacies and personal/company
donations for cancer-related activities.
• Create, strengthen and expand of regional cancer registries. Evaluate
the implementation of cancer registries to incorporate the capital
city, Santiago. Promotion of tumor banking and other national
infrastructure initiatives. The encouragement of existing initiatives to
unite under a virtual national network. Redefine the existing legal
framework for the use of human samples and clinical information, as
to not impinge on biobanking and medical research.
• Promote the formation of medical cancer specialists (e.g. oncologists,
palliative care, nursing and other cancer-related human resources).
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system. However, plans for such registries, already drawn
up by the Ministry of Health, unfortunately are not viable
to define a strategic priority. This clearly needs to change.
The analysis of cancer statistics, a clear vision of the trends
and distribution of cancer and the socio-economic needs
in Chile, are fundamental if substantially increased public
funds are going to be spent in care. Hand in hand with
care, is the need to put more funding into cancer research
as well as to take an interdisciplinary approach to integrat-
ing basic scientists and medical community, healthcare
professionals, social scientists and economists. For Chile,
as well as all other emerging economies, it is clear that a
radical shift in cancer public policy is required.
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